Curiva

Executive Summary

Curiva is a US-based diagnostics company developing the diaPatch™, a non-invasive wearable patch designed for cervical cancer risk stratification. Following an abnormal Pap smear, current standard of care often requires colposcopy, an invasive procedure associated with patient anxiety and loss to follow-up. Curiva’s technology aims to replace this with a microneedle-based fluid sampling and molecular assay platform that delivers same-visit results in approximately 30 minutes. By providing immediate risk stratification, the diaPatch™ reduces patient distress and healthcare system friction, potentially improving adherence to screening guidelines. The company’s mission is to transform cervical cancer screening into a patient-centric, rapid, and non-invasive experience. With significant market opportunity and a clear unmet need in women’s health, Curiva is positioned to disrupt the traditional diagnostic pathway. However, as a private company with no disclosed funding or regulatory milestones, execution risk remains high pending clinical validation and regulatory clearance.

Upcoming Catalysts (preview)

• Q1 2027FDA 510(k) submission for diaPatch™40% success
• Q4 2026Publication of pivotal clinical study results60% success
• Q2 2027Strategic partnership or licensing deal with a diagnostic laboratory network35% success